KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Sales and Divestitures (2021 - 2023)

Ginkgo Bioworks Holdings (DNA) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $27.2 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Gains from Sales and Divestitures rose 30390.46% year-over-year to $27.2 million, compared with a TTM value of $27.2 million through Jun 2023, up 30390.46%, and an annual FY2022 reading of $178531.0, down 99.79% over the prior year.
  • Gains from Sales and Divestitures was $27.2 million for Q2 2023 at Ginkgo Bioworks Holdings, up from $11.8 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $85.8 million in Q4 2021 and bottomed at $89264.0 in Q2 2022.
  • Average Gains from Sales and Divestitures over 3 years is $18.0 million, with a median of $622282.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures tumbled 99.79% in 2022, then surged 30390.46% in 2023.
  • Year by year, Gains from Sales and Divestitures stood at $85.8 million in 2021, then crashed by 99.79% to $178531.0 in 2022, then soared by 15144.97% to $27.2 million in 2023.
  • Business Quant data shows Gains from Sales and Divestitures for DNA at $27.2 million in Q2 2023, $11.8 million in Q1 2023, and $178531.0 in Q4 2022.